Kairos Pharma (KAPA) Research & Development (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Research & Development came in at $496000.0 in Q2 2025, up 687.3% YoY from $63000.0 in Q2 2024, and up 0.61% on a QoQ basis from $493000.0 in Q1 2025.
Kairos Pharma (KAPA) Research & Development (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Research & Development data on file, last reported at $496000.0 in Q2 2025.
- Quarterly Research & Development rose 687.3% year-over-year to $496000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.2 million (up 338.43% YoY) and the FY2025 annual result came in at $2.1 million, up 415.7% from the prior year.
- Research & Development grew to $496000.0 in Q2 2025, from $493000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $496000.0 in Q2 2025 to a low of $7000.0 in Q4 2023.
- A 3-year average of $180375.0 and a median of $114000.0 in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 2357.14% in 2024, down 57.58% in 2024.
- Tracing KAPA's Research & Development over 3 years: stood at $7000.0 in 2023, then jumped by 2357.14% to $172000.0 in 2024, then surged by 188.37% to $496000.0 in 2025.
- The last three Research & Development figures came in at $496000.0 (Q2 2025), $493000.0 (Q1 2025), and $172000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 97.90 Mn |
| 10 | Kairos Pharma | 5.34 Mn | 8,058.08 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 496,000.00 |
| Mar 31, 2025 | 493,000.00 |
| Dec 31, 2024 | 172,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 63,000.00 |
| Mar 31, 2024 | 165,000.00 |
| Dec 31, 2023 | 7,000.00 |
| Sep 30, 2023 | 33,000.00 |